View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

argenx to Present at 44th Annual J.P. Morgan Healthcare Conference

argenx to Present at 44th Annual J.P. Morgan Healthcare Conference January 6, 2026Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. PT. A live webcast of the presentation may be accessed on the Investors section of the argenx website at . A replay of the webcast will be available on the argenx...

Hilde Van Boxstael ... (+6)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Livio Luyten
  • Lynn Hautekeete
  • Wim Hoste
  • Wim Lewi
Jacob Mekhael
  • Jacob Mekhael

argenx Karen Massey to become new CEO

argenx announced that Karen Massey, current COO, will transition to CEO and executive director and Tim Van Hauwermeiren, current CEO, will transition to non-executive director and chairman of the board. We believe Karen is a strong fit for the CEO role as an internal candidate who, in her capacity as COO, helped shape the company's Vision 2030 and built its commercial engine. Based on our conversation with management, Karen will focus on ensuring continuity and executing argenx' strategy, while...

 PRESS RELEASE

argenx Announces Leadership Transition Marking Next Evolution of Growt...

argenx Announces Leadership Transition Marking Next Evolution of Growth Tim Van Hauwermeiren to transition from CEO to Non-Executive Director and Chairman of Board of Directors and Karen Massey to transition from COO to CEO and Executive Director January 5, 2026 7:00 a.m. CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karen Massey, current Chief Operating Officer, will transition to Chief Executive Officer and Executive Director an...

Guy Sips ... (+3)
  • Guy Sips
  • Hilde Van Boxstael
  • Wim Lewi
Guy Sips ... (+8)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Livio Luyten
  • Michiel Declercq
  • Thibault Leneeuw
  • Wim Lewi

Morning Notes : BAR BB, COFB BB, FAGR BB, GLPG NA, IBAB BB, DEME BB, N...

: BAR BB, COFB BB, FAGR BB, GLPG NA, IBAB BB, DEME BB, NXFIL NA, ENRGY BB

 PRESS RELEASE

DEME secures two marine works contracts in Italy and Spain

DEME secures two marine works contracts in Italy and Spain DEME’s Dredging & Infra segment has secured two marine works contracts in Southern Europe, highlighting its expertise in environmental remediation and coastal protection. In Italy, DEME will deliver marine works for the prestigious 38th America’s Cup sailing competition in Naples, including offshore breakwaters and seabed remediation at the Bagnoli-Coroglio site. Meanwhile, in Spain, DEME will restore three beaches along the Valencian coastline through a large-scale nourishment project, to combat erosion and safeguard the shoreline ...

 PRESS RELEASE

DEME haalt twee contracten binnen voor maritieme werken in Italië en S...

DEME haalt twee contracten binnen voor maritieme werken in Italië en Spanje DEME’s Dredging & Infra-segment heeft twee contracten voor maritieme werken binnengehaald in Zuid-Europa, die de expertise op het gebied van milieusanering en kustbescherming in de verf zetten. In Italië zal DEME maritieme werken uitvoeren voor de prestigieuze 38ste America’s Cup-zeilwedstrijd in Napels, waaronder golfbrekers en sanering van de zeebodem op de site Bagnoli-Coroglio. In Spanje zal DEME drie stranden langs de Valenciaanse kustlijn herstellen via een grootschalig ophogingsproject, om erosie tegen te gaa...

Guy Sips ... (+2)
  • Guy Sips
  • Kristof Samoy
 PRESS RELEASE

DEME wins contract to help restore water quality in the central Nether...

DEME wins contract to help restore water quality in the central Netherlands DEME has won a contract to implement WFD (Water Framework Directive) measures in Central Netherlands. WFD measures are projects aimed at improving water quality in the Netherlands, which are carried out by Rijkswaterstaat. In collaboration with its partner Beens Dredging B.V. (part of Beens Groep B.V.), DEME will execute Lot D at the locations Eemmeer, Ketelmeer, and Zwarte Meer. These works will start in April 2026 and are expected to be completed by December 2027. Attachment ...

 PRESS RELEASE

DEME wint contract voor herstel van waterkwaliteit in Midden-Nederland

DEME wint contract voor herstel van waterkwaliteit in Midden-Nederland DEME heeft een contract getekend voor de uitvoering van KRW-maatregelen in Midden-Nederland. KRW-maatregelen (Kaderrichtlijn Water) zijn projecten die gericht zijn op het verbeteren van de waterkwaliteit in Nederland, uitgevoerd door Rijkswaterstaat. In samenwerking met partner Beens Dredging B.V. (onderdeel van Beens Groep B.V.) zal DEME Perceel D uitvoeren op de locaties Eemmeer, Ketelmeer en Zwarte Meer. De werkzaamheden starten in april 2026 en de voltooiing wordt verwacht in december 2027. Bijlage ...

Hilde Van Boxstael ... (+7)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Livio Luyten
  • Michiel Declercq
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi
Jacob Mekhael
  • Jacob Mekhael

argenx Vyvgart phase 3 in TED stopped due to lack of efficacy

argenx announced that the phase 3 (UplighTED) studies evaluating Vyvgart subcutaneous (SC) in adults with moderate to severe thyroid eye disease (TED) will be discontinued following a pre-specified unblinded interim analysis from patients completing 24 weeks of treatment. The decision to stop the trial due to lack of efficacy in TED is disappointing, however, the company notes that its pipeline strategy anticipates attrition. Of the 2026 phase 3 readouts, TED was the only program where argenx le...

 PRESS RELEASE

argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyr...

argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease 15 December, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Phase 3 UplighTED studies evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate to severe thyroid eye disease (TED) will be discontinued. The decision is based on the recommendation from an Independent Data Monitoring ...

Guy Sips ... (+9)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Livio Luyten
  • Mathijs Geerts Danau
  • Michiel Declercq
  • Wim Hoste
  • Wim Lewi

Morning Notes : ACKB BB, AKZA NA, IBAB BB, ONTEX BB, SEQUA BB, XIOR BB...

: ACKB BB, AKZA NA, IBAB BB, ONTEX BB, SEQUA BB, XIOR BB, DEME BB, ARG FP, ZEAL DC

 PRESS RELEASE

DEME secures foundation and cable installation contracts for BC-Wind o...

DEME secures foundation and cable installation contracts for BC-Wind offshore wind farm in Poland DEME has been awarded three contracts for the installation of monopile foundations, inter-array cables, and the export cable at the BC-Wind offshore wind farm in Poland. These new contracts position DEME as a key contributor to Poland’s renewable energy build-out, supporting the country’s energy transition. Attachment

 PRESS RELEASE

DEME wint contracten voor funderings- en kabelinstallatie voor BC-Wind...

DEME wint contracten voor funderings- en kabelinstallatie voor BC-Wind offshore windpark in Polen DEME heeft drie contracten gewonnen voor de installatie van monopile funderingen, inter-arraykabels en de exportkabel voor het BC-Wind offshore windpark in Polen. Deze nieuwe contracten positioneren DEME als een belangrijke speler in de uitbouw van hernieuwbare energie in Polen en ondersteunen de energietransitie van het land. Bijlage

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch